Longitude Capital — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.
BiotechDigital HealthMedical DevicesSouth San Francisco, US
Marshall Fordyce(Executive Officer, Director)in
BoardBeth Seidenberg(Director)inMaha Katabi(Director)inKurt von Emster(Director)inPatrick Enright(Director)inAndrew Cheng(Director)
Co-investorsKleiner PerkinsSofinnova VenturesAbingworthSofinnova Venture Partners
Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy.
BiotechHealthtechAptos, US
Jason Levin(Founder, Director and Chief Executive Officer)Robert M. Myers(Executive Officer, Director)
BoardMichael Wasserman(Director)Patrick Enright(Director)inElisha (Terry) Gould(Director)Ernest Mario(Director)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge PartnersAbingworthAdams Street PartnersAgent Capital
Polares Medical is a medical device company developing a device for treating mitral valve regurgitation.
HealthtechMedical DevicesPalo Alto, US
Alex Khairkhahan(Founder)in
Co-investorsDecheng CapitalEarlybird Venture CapitalEndeavour VisionIDO Investments
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.